PapersFlow Research Brief
HER2/EGFR in Cancer Research
Research Guide
What is HER2/EGFR in Cancer Research?
HER2/EGFR in Cancer Research refers to studies on the HER2 and EGFR receptor tyrosine kinases, their amplification or mutations in cancers such as breast and lung, and targeted therapies like trastuzumab and gefitinib that improve patient outcomes in HER2-positive or EGFR-mutant tumors.
Research on HER2/EGFR examines amplification of the HER-2/neu oncogene in breast cancer, correlating it with relapse and reduced survival, as shown in primary tumors from 189 patients. Activating EGFR mutations in non-small-cell lung cancer predict responsiveness to gefitinib, with mutations identified in 15 of 58 Japanese tumors and 1 of 61 U.S. tumors. Trastuzumab combined with chemotherapy increases clinical benefit in metastatic HER2-overexpressing breast cancer, establishing HER2-targeted therapy as a standard. The field includes 62,651 works.
Topic Hierarchy
Research Sub-Topics
HER2-Positive Breast Cancer Trastuzumab
This sub-topic evaluates efficacy, resistance mechanisms, and adjuvant use of trastuzumab in early and metastatic HER2-positive breast cancer. Researchers study biomarkers predicting response and cardiotoxicity.
EGFR Mutations Lung Cancer
This sub-topic covers activating EGFR mutations, tyrosine kinase inhibitors like gefitinib, and progression-free survival in non-small cell lung cancer. Researchers analyze resistance pathways and next-generation sequencing.
HER2 EGFR Signaling Pathways
This sub-topic dissects dimerization, crosstalk, and downstream cascades in ErbB family receptors driving oncogenesis. Researchers model network dynamics and inhibitor synergies.
HER2 Targeted Combination Therapies
This sub-topic assesses dual HER2 blockade with pertuzumab plus trastuzumab alongside chemotherapy in neoadjuvant and metastatic settings. Researchers explore antibody-drug conjugates and immune modulation.
HER2 Amplification Prognosis
This sub-topic correlates HER2 overexpression with tumor aggressiveness, relapse risk, and survival using FISH/IHC assays. Researchers integrate genomic signatures for risk stratification.
Why It Matters
HER2 amplification occurs in 25 to 30 percent of primary breast cancers and links to poorer prognosis, as detailed in 'Studies of the HER-2/neu Proto-Oncogene in Human Breast and Ovarian Cancer' (Slamon et al., 1989), enabling patient stratification for targeted treatments. Trastuzumab plus chemotherapy improved outcomes in metastatic HER2-positive breast cancer, per 'Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2' (Slamon et al., 2001), which has 11,374 citations and shaped first-line therapy protocols. In gastric cancer, the ToGA trial showed trastuzumab with chemotherapy extended survival in HER2-positive advanced cases, reported in 'Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial' (Bang et al., 2010). EGFR mutations underlie gefitinib response in lung cancer, with 'Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib' (Lynch et al., 2004) identifying responsive subgroups and guiding mutation screening in clinical practice.
Reading Guide
Where to Start
'Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene' (Slamon et al., 1987) is the starting point, as it establishes the foundational link between HER2 amplification and poor prognosis in 189 primary breast tumors, providing essential context for later therapy papers.
Key Papers Explained
'Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene' (Slamon et al., 1987) first correlates HER2 amplification with outcomes, built upon by 'Studies of the HER-2/neu Proto-Oncogene in Human Breast and Ovarian Cancer' (Slamon et al., 1989) quantifying prevalence at 25-30% in breast tumors. 'Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2' (Slamon et al., 2001) translates this into therapy, showing trastuzumab benefits. Signaling insights from 'Untangling the ErbB signalling network' (Yarden and Sliwkowski, 2001) and 'Cell Signaling by Receptor Tyrosine Kinases' (Lemmon and Schlessinger, 2010) explain mechanisms. EGFR parallels appear in 'Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib' (Lynch et al., 2004) and 'EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy' (Paez et al., 2004).
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current work extends to combination therapies like trastuzumab with chemotherapy in gastric cancer, as in the ToGA trial (Bang et al., 2010), and integrates gene signatures for prognosis from 'A Gene-Expression Signature as a Predictor of Survival in Breast Cancer' (van de Vijver et al., 2002) and Oncotype DX validation (Paik et al., 2004). No recent preprints or news available.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Human Breast Cancer: Correlation of Relapse and Survival with ... | 1987 | Science | 11.6K | ✕ |
| 2 | Activating Mutations in the Epidermal Growth Factor Receptor U... | 2004 | New England Journal of... | 11.4K | ✕ |
| 3 | Use of Chemotherapy plus a Monoclonal Antibody against HER2 fo... | 2001 | New England Journal of... | 11.4K | ✓ |
| 4 | <i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinica... | 2004 | Science | 9.3K | ✕ |
| 5 | Cell Signaling by Receptor Tyrosine Kinases | 2010 | Cell | 7.8K | ✓ |
| 6 | Trastuzumab in combination with chemotherapy versus chemothera... | 2010 | The Lancet | 7.1K | ✓ |
| 7 | Untangling the ErbB signalling network | 2001 | Nature Reviews Molecul... | 6.8K | ✕ |
| 8 | Studies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breas... | 1989 | Science | 6.8K | ✕ |
| 9 | A Gene-Expression Signature as a Predictor of Survival in Brea... | 2002 | New England Journal of... | 6.5K | ✓ |
| 10 | A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, ... | 2004 | New England Journal of... | 6.2K | ✓ |
Frequently Asked Questions
What is the correlation between HER2 amplification and breast cancer outcomes?
HER2/neu oncogene amplification correlates with relapse and reduced survival in breast cancer, as shown in 189 primary tumors in 'Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene' (Slamon et al., 1987). This alteration occurs in breast cancer cell lines and primary tumors. It serves as a prognostic marker.
How do EGFR mutations affect lung cancer treatment?
Activating EGFR mutations in non-small-cell lung cancer correlate with responsiveness to gefitinib, found in 15 of 58 Japanese tumors and 1 of 61 U.S. tumors, per 'EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy' (Paez et al., 2004). These mutations increase growth factor signaling and susceptibility to tyrosine kinase inhibitors. Screening for EGFR mutations guides therapy selection.
What is the role of trastuzumab in HER2-positive breast cancer?
Trastuzumab combined with chemotherapy provides clinical benefit in first-line treatment of metastatic HER2-overexpressing breast cancer, as demonstrated in 'Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2' (Slamon et al., 2001). It targets HER2 overexpression. This approach improves survival over chemotherapy alone.
What mechanisms underlie HER2 and EGFR signaling?
HER2 and EGFR are receptor tyrosine kinases that signal through pathways like those detailed in 'Cell Signaling by Receptor Tyrosine Kinases' (Lemmon and Schlessinger, 2010). The ErbB network involves ligand binding and dimerization, per 'Untangling the ErbB signalling network' (Yarden and Sliwkowski, 2001). These processes drive cancer progression when dysregulated.
How prevalent is HER2 amplification in breast cancer?
HER-2/neu proto-oncogene amplification occurs in 25 to 30 percent of primary breast cancers, according to 'Studies of the HER-2/neu Proto-Oncogene in Human Breast and Ovarian Cancer' (Slamon et al., 1989). It associates with aggressive disease. This frequency supports routine testing for targeted therapies.
Open Research Questions
- ? How do resistance mechanisms develop to trastuzumab in HER2-positive breast cancer despite initial responses?
- ? What combinations of EGFR inhibitors with other agents overcome mutations in non-small-cell lung cancer?
- ? How does neuregulin 1 or ADAM metalloproteinases modulate HER2 signaling in tumor progression?
- ? Can gene-expression signatures incorporating HER2/EGFR refine survival predictions beyond current assays?
- ? What structural features of HER2/EGFR dimers inform next-generation inhibitor design?
Recent Trends
The field spans 62,651 works with foundational papers like 'Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene' (Slamon et al., 1987, 11,617 citations) leading to therapies in 'Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2' (Slamon et al., 2001, 11,374 citations).
EGFR mutation insights from 2004 papers (Lynch et al. and Paez et al.) sustain interest in lung cancer targeting.
No growth rate, recent preprints, or news reported.
Research HER2/EGFR in Cancer Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching HER2/EGFR in Cancer Research with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers